This observation strongly suggests that the unique features of basal-like breast cancers (poor clinical outcomes, variable response to chemotherapy and recurrence following chemotherapy) may be a direct consequence of methylation-dependent gene silencing events associated with DNMT3b overexpression. The gene discussed is DNMT3B; the disease is breast cancer.